AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3
EDi001-A-2
General
Cell Line |
|
| hPSCreg name | EDi001-A-2 |
| Cite as: | EDi001-A-2 (RRID:CVCL_LE52) |
| Alternative name(s) |
AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi008-B (G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease HIHDNDi001-B (A30P-4, SNCA4, Tue_020_B) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 HIHDNDi001-A (A30P-3, SNCA3, Tue_020_A) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: autosomal dominant Parkinson disease 1 |
| Last update | 14th May 2022 |
| User feedback | |
Provider |
|
| Generator | University of Edinburgh (ED) |
| Owner | College of Medicine and Veterinary Medicine |
| Distributors | |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA3323846 |
| Cellosaurus | CVCL_LE52 |
| Wikidata | Q54831973 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | Strong family history of Parkinson’s disease due to autosomal dominant inheritance of SNCA triplication |
| Is the medical history available upon request? | Y Mov Disord. 2011 Sep;26(11):2134-6. doi: 10.1002/mds.23776 |
Donor Relations |
|
| Other cell lines of this donor | |
| All cell lines of this donor's relatives |
Has daughter:
|
External Databases (Donor) |
|
| BioSamples | SAMEA3319991 |
Ethics
Also have a look at the ethics information for the parental line
EDi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
EDi001-A.
|
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Nickase pair mediated SNCA Knock-out of 1 SNCA alleles. Therefore 3 alleles remain. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Laminin | ||||||
| Passage method |
Enzymatically
Accutase
|
||||||
| O2 Concentration | 20 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Essential 8™
Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| SSEA-1 |
No |
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
59
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.